Table of Contents Author Guidelines Submit a Manuscript
Schizophrenia Research and Treatment
Volume 2012, Article ID 540273, 8 pages
http://dx.doi.org/10.1155/2012/540273
Review Article

The Role of Oestrogen and Other Hormones in the Pathophysiology and Treatment of Schizophrenia

Monash Alfred Psychiatry Research Centre, The Alfred Hospital and Monash University School of Psychology, Psychiatry and Psychological Medicine, Melbourne, VIC 3004, Australia

Received 10 November 2011; Accepted 7 December 2011

Academic Editor: Judith Usall

Copyright © 2012 Emily Hayes et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Citations to this Article [18 citations]

The following is the list of published articles that have cited the current article.

  • Malgorzata Kowalczyk, Aleksander Owczarek, Renata Suchanek, Monika Paul-Samojedny, Anna Fila-Danilow, Paulina Borkowska, Krzysztof Kucia, and Jan Kowalski, “Heat shock protein 70 gene polymorphisms are associated with paranoid schizophrenia in the Polish population,” Cell Stress and Chaperones, 2013. View at Publisher · View at Google Scholar
  • Sven Haedel, Christoph Wirth, Michael Rapp, Juergen Gallinat, and Florian Schubert, “Effects of Age and Sex on the Concentrations of Glutamate and Glutamine in the Human Brain,” Journal of Magnetic Resonance Imaging, vol. 38, no. 6, pp. 1480–1487, 2013. View at Publisher · View at Google Scholar
  • Michael C. Davis, William P. Horan, and Stephen R. Marder, “Psychopharmacology of the Negative Symptoms of Schizophrenia: Current Status and Prospects for Progress,” European Neuropsychopharmacology, 2013. View at Publisher · View at Google Scholar
  • Keith A. Feigenson, Alex W. Kusnecov, and Steven M. Silverstein, “Inflammation and the two-hit hypothesis of schizophrenia,” Neuroscience & Biobehavioral Reviews, 2013. View at Publisher · View at Google Scholar
  • Elise Hall, and Meir Steiner, “Serotonin and female psychopathology,” Women's Health, vol. 9, no. 1, pp. 85–97, 2013. View at Publisher · View at Google Scholar
  • Hanan D. Trotman, Carrie W. Holtzman, Daniel I. Shapiro, Allison N. MacDonald, Sandra M. Goulding, Arthur T. Ryan, Joy L. Brasfield, and Elaine F. Walker, “The development of psychotic disorders in adolescence: A potential role for hormones,” Hormones And Behavior, vol. 64, no. 2, pp. 411–419, 2013. View at Publisher · View at Google Scholar
  • Dolores Malaspina, Julie Walsh-Messinger, Wolfgang Gaebel, Lianne Morris Smith, Alyson Gorun, Vasthie Prudent, Daniel Antonius, and Fabien Tremeau, “Negative symptoms, past and present: A historical perspective and moving to DSM-5,” European Neuropsychopharmacology, vol. 24, no. 5, pp. 710–724, 2014. View at Publisher · View at Google Scholar
  • J.-P. Klemettilä, O. Kampman, N. Seppälä, M. Viikki, M. Hämäläinen, E. Moilanen, N. Mononen, T. Lehtimäki, and E. Leinonen, “Association study of the HTR2C, leptin and adiponectin genes and serum marker analyses in clozapine treated long-term patients with schizophrenia,” European Psychiatry, 2014. View at Publisher · View at Google Scholar
  • Kim Donoghue, Gillian A. Doody, Robin M. Murray, Peter B. Jones, Craig Morgan, Paola Dazzan, Jozella Hart, Rodolfo Mazzoncini, and James H. MacCabe, “Cannabis use, gender and age of onset of schizophrenia: Data from the ÆSOP study,” Psychiatry Research, 2014. View at Publisher · View at Google Scholar
  • Jancy Jose, H. Nandeesha, Shivanand Kattimani, Kavitha Meiyappan, Siddharth Sarkar, and Devanarayanan S, “Association between prolactin and thyroid hormones with severity of psychopathology and suicide risk in drug free male schizophrenia,” Clinica Chimica Acta, 2015. View at Publisher · View at Google Scholar
  • Mikael Mokkonen, and Bernard J. Crespi, “Genomic conflicts and sexual antagonism in human health: insights from oxytocin and testosterone,” Evolutionary Applications, 2015. View at Publisher · View at Google Scholar
  • M.-A. Lodovighi, A. Palomba, R. Belzeaux, M. Adida, and J.-M. Azorin, “Symptômes négatifs de la schizophrénie : nouvelles approches pharmacologiques,” L'Encéphale, vol. 41, no. 6, pp. 6S41–6S49, 2015. View at Publisher · View at Google Scholar
  • Andrea Gogos, Alyssa M. Sbisa, Jeehae Sun, Andrew Gibbons, Madhara Udawela, and Brian Dean, “A Role for Estrogen in Schizophrenia: Clinical and Preclinical Findings,” International Journal of Endocrinology, vol. 2015, pp. 1–16, 2015. View at Publisher · View at Google Scholar
  • Anand Gururajan, and Daniel Thomas Malone, “Does cannabidiol have a role in the treatment of schizophrenia?,” Schizophrenia Research, 2016. View at Publisher · View at Google Scholar
  • Wan Lian LC Chua, Hristo S Grigorov, and John HileyCochrane Database of Systematic Reviews, 2016. View at Publisher · View at Google Scholar
  • Forough Riahi, Maryam Izadi-mazidi, Ali Ghaffari, Elham Yousefi, and Shahram Khademvatan, “Comparison of Plasma Neurosteroid and Prolactin Levels in Patients with Schizophrenia and Healthy Individuals,” Scientifica, vol. 2016, pp. 1–6, 2016. View at Publisher · View at Google Scholar
  • Michal Arad, Yael Piontkewitz, Noa Albelda, Lee Shaashua, and Ina Weiner, “Immune activation in lactating dams alters sucklings' brain cytokines and produces non-overlapping behavioral deficits in adult female and male offspring: A novel neurodevelopmental model of sex-specific psychopathology,” Brain, Behavior, and Immunity, 2017. View at Publisher · View at Google Scholar
  • Aleida Frissen, Jim van Os, Sanne Peeters, Ed Gronenschild, and Machteld Marcelis, “Evidence that reduced gray matter volume in psychotic disorder is associated with exposure to environmental risk factors,” Psychiatry Research: Neuroimaging, 2017. View at Publisher · View at Google Scholar